SCHEMBL2345997

SCHEMBL2345997

CNC(=O)C(O)(O)C1CCCNC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A1 P30531 2/20 0.39
SLC6A11 P48066 1/20 0.39
TSHR P16473 1/20 0.39
LMNA P02545 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
SLC6A13 Q9NSD5 1/20 0.39
KMT2A Q03164 2/20 0.38
KDM4E B2RXH2 1/20 0.38
MAPT P10636 1/20 0.38
ATM Q13315 1/20 0.38
CYP2D6 P10635 1/20 0.38
SSTR4 P31391 2/20 0.35
CPN1 P15169 2/20 0.32
CPB2 Q96IY4 2/20 0.32
MAPK1 P28482 1/20 0.31
OPRK1 P41145 1/20 0.31
APLNR P35414 2/20 0.31
NOS2 P35228 1/20 0.31
EPHX1 P07099 1/20 0.31
CCR2 P41597 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2346003 0.75 SLC6A1 (0.38) SLC6A1SLC6A11TSHRLMNASMN1; SMN2
SCHEMBL29332278 0.71 SLC6A1 (0.46) SLC6A1SLC6A11TSHRLMNASMN1; SMN2
SCHEMBL2346902 0.71 KDM4E (0.38) KMT2AKDM4ECYP2D6MAPK1CCR2
SCHEMBL13527922 0.71 SLC6A1 (0.39) SLC6A1SLC6A11TSHRLMNASMN1; SMN2
SCHEMBL2673795 0.71 SLC6A1 (0.39) SLC6A1SLC6A11TSHRLMNASMN1; SMN2
SCHEMBL3183446 0.71 SLC6A1 (0.39) SLC6A1SLC6A11TSHRLMNASMN1; SMN2
SCHEMBL29332975 0.70 SSTR4 (0.34) SLC6A1SLC6A11TSHRLMNASMN1; SMN2
SCHEMBL1047564 0.70 SLC6A1 (0.40) SLC6A1SLC6A11TSHRLMNASMN1; SMN2
SCHEMBL29332215 0.70 SSTR4 (0.34) SLC6A1SLC6A11TSHRLMNASMN1; SMN2
Hydrochloric Acid SCHEMBL3165782 0.70 SLC6A1 (0.38) SLC6A1SLC6A11TSHRLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110237538-A1 TREATMENT OF LYSOSOMAL STORAGE DISORDERS AND OTHER PROTEOSTATIC DISEASES SUMMIT CORPORATION PLC (GB) 2011-09-29 US disclosed
US-20110195929-A1 COMPOUNDS FOR THE TREATMENT OF FLAVIVIRAL INFECTIONS SUMMIT CORPORATION PLC (GB) 2011-08-11 US disclosed
WO-2010049678-A2 TREATMENT OF ENERGY UTILIZATION DISEASES SUMMIT CORPORATION PLC (GB) 2010-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237538-A1 TREATMENT OF LYSOSOMAL STORAGE DISORDERS AND OTHER PROTEOSTATIC DISEASES GAA, MAN2B1, GBA1 SLC6A1 4294/4885SLC6A11 4333/4885TSHR 3716/4885
US-20110195929-A1 COMPOUNDS FOR THE TREATMENT OF FLAVIVIRAL INFECTIONS GPI, GALE, HAVCR2 SLC6A1 2251/4885SLC6A11 2227/4885TSHR 4184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.